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Abstract
Adjuvant chemotherapy is a standard treatment for operable gastric cancer. However, 
the preferred treatment varies by geographical region. Southwestern Oncology Group 
(SWOG) conducted a, randomized trial of adjuvant chemotherapy for patients with surgi-
cally resected gastric cancer. The 3-year survival rates were 50% in the chemoradiothera-
pygroup and 41% in the surgery group. The Medical Research Council Adjuvant Gastric 
Infusional Chemotherapy (MAGIC) trial that compared perioperative chemotherapy with 
the ECF regimen (epirubicin, cisplatin, and 5-fluorouracil) and patients with surgery alone 
had a 5-year survival rate of 36 and 23%. The Adjuvant Chemotherapy Trial of TS-1 for 
Gastric Cancer (ACTS-GC) showed that the 3-year overall survival rate was 80.1% in the 
S-1 group and 70.1% in the surgery-only group in stage II or III gastric cancer patients who 
underwent a D2 gastrectomy. An analysis of the Capecitabine and Oxaliplatin Adjuvant 
Study in Stomach Cancer (CLASSIC) study showed 3-year disease-free survival, 74% in the 
chemotherapy and surgery group and 59% in the surgery-only group in the patients with 
stage II–IIIB gastric cancer who had D2 gastrectomy. In conclusion, for all patients with 
stage II and III gastric cancer, standard D2 gastrectomy and adjuvant chemotherapy are 
strongly recommended for improved survival rates.
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1. Introduction
Gastric cancer is the second most common cause of cancer-related death worldwide [1]. 
Radical operation is the main treatment for gastric cancer, but the recurrence rate follow-
ing surgery is high due to the early dissemination of cancer cells via the lymphatic sys-
tem (about 40–80% in advanced gastric cancer) [1, 2]. In East Asia, especially Japan and 
Korea, D2 lymph node dissection is the standard treatment for operable gastric cancer [3, 4]. 
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However, in the Western world, D2 gastrectomy is not as widely performed as in Japan and 
Korea [5]. Western surgical studies have shown that most patients present with tumors that 
penetrated the submucosa; they have a 5-year survival rate of 20–30% [6]. Postoperative che-
motherapy is a standard treatment component of resectable gastric cancer and has improved 
patient outcomes [3, 4]. Treatment results of adjuvant chemotherapy may depend on the 
interaction between residual cancers and anticancer drugs. The Japanese recommendation 
for adjuvant chemotherapy is based on the Adjuvant Chemotherapy Trial of TS-1 for Gastric 
Cancer (ACTS-GC) study, which showed a survival benefit with adjuvant chemotherapy 
after D2 gastrectomy compared with surgery alone [4]. This study showed a survival ben-
efit for stage II and IIIA gastric cancer [4]. However, the FLAGS trial for advanced gastric 
cancer or gastroesophageal cancer that compared cisplatin and S-1 versus cisplatin and 
fluorouracil in non-Asian countries did not prolong overall survival [7]. In Korea, adjuvant 
immunochemotherapy in advanced gastric cancer patients, who had undergone radical 
subtotal gastrectomy for stage III gastric cancer has been performed. For immunotherapy, 
a Streptococcus pyogenes preparation (picibanil) was followed by MF (mitomycin C and 
5-FU) in the late 1990s and early 2000s [3, 8]. The Capecitabine and Oxaliplatin Adjuvant 
Study in Stomach Cancer (CLASSIC) study was designed to compare the effect of adjuvant 
capecitabine plus oxaliplatin after D-2 gastrectomy with stage II or III gastric cancer [1]. 
Although adjuvant chemotherapy is a standard treatment option for operable gastric cancer, 
there have been some differences concerning methods of chemotherapy and survival data 
between the Western world (Europe and North America) and East Asia (Korea and Japan). 
Therefore, this article summarizes the adjuvant chemotherapy for resectable gastric cancer 
using a medical literature review.
2. Treatment results with adjuvant chemotherapy
Treatment results of adjuvant chemotherapy may depend on the interaction between residual 
tumor and anticancer drugs. The tumor burden should be reduced as much as possible to 
obtain the most optimal survival benefit of adjuvant chemotherapy [10]. As compared to 
Western countries, the high survival rate in East Asia might have resulted from a selection 
of early-stage patients and radical operations, including systematic lymph node dissection 
[10]. The Southwestern Oncology Group (SWOG) conducted a two-armed prospective, ran-
domized trial of adjuvant chemotherapy for patients with gastric adenocarcinoma surgically 
resected to negative margins (Table 1). Most patients (54%) had undergone a D0 dissection, 
which is less than a complete dissection of the N1 nodes. The chemotherapy regimen included 
fluorouracil, 425 mg/m2 of body-surface area per day, and leucovorin, 20 mg, followed by 
radiotherapy of 4500 cGy of radiation at 180 cGy/day. The median survival time in the sur-
gery group was 27 months as compared with 36 months in the chemoradiotherapy group [5]. 
The 3-year survival rates were 50% in the chemoradiotherapy group and 41% in the surgery-
only group [5, 11]. The 503-patient United Kingdom National Cancer Research Institute 
(NCRI) Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) trial 
was the first randomized trial to demonstrate the survival benefit from the use of periopera-
tive chemotherapy for patients with resectable gastric cancer compared with surgery alone. 
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The patients who received perioperative chemotherapy with the ECF regimen (epirubicin, cis-
platin, and 5-fluorouracil, 5FU) had a 5-year survival of 36%, compared with 23% in patients 
treated with surgery alone [12] (Table 1). Kim et al. evaluated 10,783 consecutive patients who 
underwent operation for gastric cancer [3]. The prognostic significance of treatment modality 
(surgery alone, surgery + chemotherapy, surgery + immunotherapy + chemotherapy <immu-
nochemotherapeutic treatment>) was evaluated for stage III gastric cancer. The protocol for 
immunochemotherapy was as follows: Picibanil (a Streptococcus pyogenes preparation; Tokyo, 
Japan), mitomycin C 4 mg/50 kg, and 5-FU 500 mg/50 kg. They concluded that radical lymph 
node dissection, with more than 25 resected lymph nodes, improved survival in patients with 
stage II and IIIc disease; as postoperative adjuvant therapy, immunochemotherapy was most 
effective in patients with stage III disease. There were significant differences in survival in 
stage III patients; the 5-year survival rates were 44.8% for the immunochemotherapy group, 
36.8% for the surgery + chemotherapy group, 36.8% for the surgery + chemotherapy group, 
and 27.1% for the surgery-alone group [3]. In the meta-analysis, which assessed entitled adju-
vant chemotherapy after curative resection for gastric cancer in Non-Asian patients, Earle 
et al. concluded adjuvant chemotherapy may produce a small survival benefit of borderline 
statistical significance in patients with curatively resected gastric carcinoma [13]. Sakuramoto 
et al. reported that patients with stage II or III gastric cancer who underwent gastrectomy with 
extended (D2) lymph node dissection were randomly assigned to undergo surgery followed 
by adjuvant chemotherapy with S-1 or to undergo surgery only. The analysis of the follow-up 
data showed that the 3-year overall survival rate was 80.1% in the S-1 group and 70.1% in the 
surgery-only group [4]. Consecutive results of the ACT-GC trial showed the overall survival 
rate at 5 years was 71.1% in the S-1 group and 61.1% in the surgery-only group (Table 1) [9]. 
In the Capecitabine and Oxaliplatin Adjuvant Study in Stomach Cancer (CLASSIC) trial, the 
patients with stage II–IIIB gastric cancer who had curative D2 gastrectomy were randomly 
assigned to receive adjuvant chemotherapy of eight cycles of oral capecitabine (1000 mg/m2 
twice daily on days 1–14 of each cycle) plus intravenous oxaliplatin (130 mg/m2 on day 1 of 
each cycle) for 6 months or surgery only. The 3-year disease-free survival was 74% in the 
Study Regimen (surgery + chemotherapy surgery alone) No. of 
patients
3-YSR 
(%)
5-YSR (%)
Macdonald et al. [5] 5FU + leucovorin + radiotherapy 281 50 40
Control 275 41 30
Cunningham et al. [6] Epirubicin + cisplatin +5FU 250 45 36
Control 253 30 23
Sakuramoto et al. [4, 9] S-1 529 80 71
Control 530 61 70
Bang et al. [1, 2] Capecitabine + oxaliplatin 520 83 78
Control 515 78 69
YSR, year survival rate.
Table 1. Adjuvant chemotherapy compared to the surgical control of curative resection of stomach cancer.
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chemotherapy and surgery group and 59% in the surgery-only group. They concluded that 
adjuvant capecitabine plus oxaliplatin treatment after curative D2 gastrectomy should be con-
sidered as a treatment option for patients with operable gastric cancer [1].
3. Discussion
Adjuvant chemotherapy is a standard treatment option for operable gastric cancer and 
improves patient outcomes, but the preferred treatment differs by geographical region [10]. 
The recommended adjuvant treatment is chemoradiotherapy in the United States and periop-
erative chemotherapy in the United Kingdom and some parts of Europe [1, 5, 12]. The Japanese 
ACT-GC trial was the first large-scale randomized trial of adjuvant chemotherapy after cura-
tive resection with D2 gastrectomy [4]. In the Republic of Korea, the CLASSIC trial was the 
second large-scale randomized trial after D2 gastrectomy [1]. The survival rate of two Asian 
large-scale randomized trials was substantially higher than in the US Intergroup-0116 and UK 
MAGIC trials (78% in the CLASSIC trial, 80% in ACT-GC vs. 30–40% in the Intergroup-0116 
and MAGIC trials) [1, 4, 5, 12]. Most recurrences after surgery of gastric cancer occurred within 
3 years of surgery [14]. The duration of adjuvant chemotherapy differed from previous stud-
ies. Kim et al. had adjuvant chemotherapy for 24 months [3]. The ACT-GC trial had adjuvant 
chemotherapy for 12 months [4]. CLASSIC trial had adjuvant chemotherapy 6 months [1]. 
The duration of adjuvant chemotherapy after surgery was different, although similar survival 
results were present in two clinical trials. Kim et al. reported that radical lymph node dissec-
tion, with more than 25 resected lymph nodes, improved survival in patients with stage II and 
IIIa disease [3]. Postoperative immunochemotherapy was most effective in patients with stage 
II and III disease [3]. The favorable outcomes of Asian studies were a result of the consistent 
adoption of D2 gastrectomy and the quality control of surgery using video techniques [1, 4]. 
But postoperative chemoradiotherapy in the United States and perioperative chemotherapy in 
Europe is not based on D2 gastrectomy. In the Intergroup-0116 study, quality assessment was 
done for radiotherapy before the initiation of this treatment [5]. However quality control of 
surgery was not done, because patients were usually identified postoperatively, and they could 
not require specific surgical procedures. Only 10% of the patients underwent a D2 dissection, 
while 36% had a D1 dissection, and 54% had a D0 lymphadenectomy (a resection in which 
not all of the N1 nodes were removed) [5]. The low long-term survival rate of stomach can-
cer patients in Western studies might result from excessive residual tumor left behind during 
surgery. The high survival rate in countries such as South Korea and Japan might be the reflec-
tion of the small amount of residual tumor due to radical gastrectomy and extensive lymph 
node dissection [10]. Songun et al. [15] reported that after a median follow-up of 15 years, D2 
lymphadenectomy with strict quality control is associated with lower locoregional recurrence 
and gastric cancer-related death rates in patients with stage II and IIIa disease than D1 surgery; 
they recommended D2 resection as the standard surgical approach to resectable gastric can-
cer [15]. The CLASSIC and ACT-GC trials showed the effectiveness of postoperative adjuvant 
chemotherapy with S-1 and XELOX for stage II and III gastric cancer patients who underwent 
D2 gastrectomy [1, 4]. Biological aspects may cause the different gastric cancer results between 
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East Asia and the Western world. However, no significant differences in prognostic factors 
were reported between these two regions of the world. In conclusion, for all patients with stage 
II and III gastric cancer worldwide, standard D2 gastrectomy and adjuvant chemotherapy are 
strongly recommended for a better rate of survival.
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